JP2020520955A5 - - Google Patents

Info

Publication number

JP2020520955A5

JP2020520955A5 JP2019564506A JP2019564506A JP2020520955A5 JP 2020520955 A5 JP2020520955 A5 JP 2020520955A5 JP 2019564506 A JP2019564506 A JP 2019564506A JP 2019564506 A JP2019564506 A JP 2019564506A JP 2020520955 A5 JP2020520955 A5 JP 2020520955A5

Authority

JP

Japan

Prior art keywords

formula

compound according

alkyl

compound

hydrogen

Prior art date

2018-05-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 151
• 125000000217 alkyl group Chemical group 0.000 claims description 66
• 150000003839 salts Chemical class 0.000 claims description 59
• 229910052739 hydrogen Inorganic materials 0.000 claims description 51
• 239000001257 hydrogen Substances 0.000 claims description 51
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 41
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 39
• 125000005843 halogen group Chemical group 0.000 claims description 36
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
• 125000003545 alkoxy group Chemical group 0.000 claims description 28
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
• 150000002431 hydrogen Chemical class 0.000 claims description 23
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
• 125000001072 heteroaryl group Chemical group 0.000 claims description 18
• 238000000034 method Methods 0.000 claims description 18
• 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 12
• 125000003118 aryl group Chemical group 0.000 claims description 12
• 125000000623 heterocyclic group Chemical group 0.000 claims description 12
• 229910052757 nitrogen Inorganic materials 0.000 claims description 12
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
• 125000005842 heteroatom Chemical group 0.000 claims description 10
• 238000004519 manufacturing process Methods 0.000 claims description 10
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
• 229910052760 oxygen Inorganic materials 0.000 claims description 10
• 239000001301 oxygen Chemical group 0.000 claims description 10
• 125000001424 substituent group Chemical group 0.000 claims description 10
• 229910052717 sulfur Chemical group 0.000 claims description 10
• 239000011593 sulfur Chemical group 0.000 claims description 10
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• -1 cyano, hydroxy Chemical group 0.000 claims description 5
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
• 125000002252 acyl group Chemical group 0.000 claims description 4
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 2
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
• 229910052799 carbon Inorganic materials 0.000 claims description 2
• 206010009887 colitis Diseases 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
• 238000002560 therapeutic procedure Methods 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 2
• 0 CNS(C[C@](CC1)CC[C@@]1N(C)c1c(cc[n]2C(N(C)CCN(C)C(OCc(cc3[N+]([O-])=O)ccc3O[C@@]([C@@]([C@]([C@]3O)O)O)O[C@]3C(O)=O)=O)=*)c2ncn1)(=O)=O Chemical compound CNS(C[C@](CC1)CC[C@@]1N(C)c1c(cc[n]2C(N(C)CCN(C)C(OCc(cc3[N+]([O-])=O)ccc3O[C@@]([C@@]([C@]([C@]3O)O)O)O[C@]3C(O)=O)=O)=*)c2ncn1)(=O)=O 0.000 description 2
• JLEDIILVPLGUCF-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)[n]1ncc(C)c1)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)[n]1ncc(C)c1)(=O)=O JLEDIILVPLGUCF-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1